Ectasia after keratorefractive surgery: Analysis of risk factors and treatment outcomes in the Indian population

角膜屈光手术后角膜扩张:印度人群风险因素和治疗结果分析

阅读:1

Abstract

PURPOSE: To analyze the risk factors in eyes developing ectasia following keratorefractive procedures. In addition, the study assessed visual outcomes following various treatment modalities for ectasia. METHODS: In this retrospective study, data of patients who underwent keratorefractive procedures, presenting to the refractive services of a tertiary eye care hospital in South India between January 2016 and May 2019 was analyzed. Of these, the eyes that developed ectasia were noted and the possible risk factors were determined. Visual outcomes following treatment with corneal collagen crosslinking (CXL) with or without intracorneal ring segment implantation (ICRS) or topography-guided corneal ablation (T-PRK) were analyzed. RESULTS: Forty eyes of 26 patients developed ectasia following keratorefractive procedures, with a mean interval of 73.1± 45.4 months between primary procedure and ectasia development. Of these, 14 patients had bilateral presentation. Identifiable risk factors included ablation depth > 75 μm (59.25%), percentage of tissue altered (PTA) > 40% (48.14%), residual stromal bed < 300 μm (22.22%), mean refractive spherical equivalent > 8 D (25.92%), inferior-superior (I-S) asymmetry > 1.4D (7.40%), central corneal thickness (CCT) < 500 μm (7.40%), Belin Ambrosio Display (BAD) > 2.5 (7.40%), posterior float elevation maximum ≥18 μm (3.70%), and pellucid marginal degeneration (PMD; 3.70%). CONCLUSION: Our study shows that only 70% of the eyes demonstrated an identifiable risk factor for the development of ectasia. Ablation depth of > 75 μm and the PTA > 40% were the most common risk factors. Treatment following CXL with ICRS or T-PRK demonstrated significantly better visual outcomes in comparison with CXL alone.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。